KIMS receives NSE listing approval for 1.99 crore QIP equity shares at Rs. 2/- par
The NSE General Updates filing dated 23 June 2026 confirms receipt of listing approval for 1,98,67,549 shares at Rs. 2/- par value each through qualified institutional placement. The listing intimation confirms that the QIP mechanism has progressed to the post-allotment listing stage. QIPs under SEBI Regulations allow listed companies to raise capital from qualifying institutional investors (mutual funds, insurance companies, foreign institutional investors) without a public offering prospectus. The Rs. 2/- per share figure represents the nominal/par value; the actual subscription price would have been determined at the QIP pricing window and disclosed separately in the board/institutional…
Why it mattersQIP listing completion under Securities and Exchange Board of India (SEBI) QIP framework requires exchange approval before share allotment becomes effective; this NSE intimation signals final listing clearance and institutional subscription closure.
SectorPharma & Healthcare
Value₹3.97 cr (nominal)
[object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Corporate Archive - KIMS Intimation Filing · official
- NSE Exchange Platform - KIMS Filings Archive · official
- SEBI (ICDR) Regulations, 2018 - Official Gazette Text · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- SEBI public issues / DRHPs · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026